| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 07/23/2013 | US8491933 Pharmaceutical compositions of semi-ordered drugs and polymers |
| 07/23/2013 | US8491932 Compositions for the oral delivery of corticosteroids |
| 07/23/2013 | US8491931 Treatment of faecal incontinence and other conditions with 1R, 2S-methoxamine |
| 07/23/2013 | US8491930 Pharmaceutical formulation containing ibuprofen and codeine |
| 07/23/2013 | US8491929 Bioadhesive polymers |
| 07/23/2013 | US8491928 Dermatological compositions comprising avermectin nanocapsules |
| 07/23/2013 | US8491927 Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
| 07/23/2013 | US8491926 Method and system for automatic or manual evaluation to provide targeted and individualized delivery of cosmetic actives in a mask or patch form |
| 07/23/2013 | US8491919 Prebiotic compositions for use with probiotics to increase probiotic growth rate and activity |
| 07/23/2013 | US8491912 Methods of treating ocular and other diseases with Syn-134R polypeptide |
| 07/23/2013 | US8491572 Instrumented orthopedic and other medical implants |
| 07/23/2013 | US8491571 Orifice device having multiple channels with varying flow rates for drug delivery |
| 07/23/2013 | US8491534 Preparation for body surface application and preparation for body surface application-holding sheet |
| 07/23/2013 | CA2717679C Aqueous pharmaceutical compositions containing borate-polyol complexes |
| 07/23/2013 | CA2681302C Proliposomal and liposomal compositions of poorly water-soluble compounds |
| 07/23/2013 | CA2679504C Personal care product comprising cyclodextrin as fragrance-complexing material |
| 07/23/2013 | CA2604078C Enteric pharmaceutical formulations of choline salt of fenofibric acid |
| 07/23/2013 | CA2601011C Sugar-coated pill |
| 07/23/2013 | CA2586074C Ophthalmic oil-in-water type emulsion with stable positive zeta potential |
| 07/23/2013 | CA2581373C Sealed, edible film strip packets and methods of making and using them |
| 07/23/2013 | CA2560226C Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient |
| 07/23/2013 | CA2514646C Factor viii polypeptide |
| 07/23/2013 | CA2471968C Immunostimulatory nucleic acids and use thereof |
| 07/23/2013 | CA2377357C Fish serine proteinases and their pharmaceutical and cosmetic use |
| 07/23/2013 | CA2332963C Combination meningitidis b/c vaccines |
| 07/23/2013 | CA2203843C Liposome-encapsulated poly iclc |
| 07/18/2013 | WO2013106852A1 Controlled delivery of tlr agonists in structural polymeric devices |
| 07/18/2013 | WO2013106824A1 Epherin receptor targeting agents |
| 07/18/2013 | WO2013106732A1 Pharmaceutical compositions and methods for their preparation |
| 07/18/2013 | WO2013106696A1 Romidepsin formulations and uses thereof |
| 07/18/2013 | WO2013106647A1 Supercritical guggul extracts and uses thereof |
| 07/18/2013 | WO2013106601A1 Pediatric oral suspension formulations of amoxicillin and clavulanate potassium and method for using same |
| 07/18/2013 | WO2013106526A1 Saxagliptin parmaceutical formulations |
| 07/18/2013 | WO2013106506A1 Stabilized pharmaceutical formulations of a potent hcv inhibitor |
| 07/18/2013 | WO2013106433A1 Cellulose derivatives for inhibiting crystallization of poorly water-soluble drugs |
| 07/18/2013 | WO2013106117A2 Nanoparticles for controlling bleeding and drug delivery |
| 07/18/2013 | WO2013106086A1 Compositions comprising crosslinked cation-binding polymers and uses thereof |
| 07/18/2013 | WO2013106073A1 Compositions comprising crosslinked cation-binding polymers and uses thereof |
| 07/18/2013 | WO2013106072A1 Compositions comprising crosslinked cation-binding polymers and uses thereof |
| 07/18/2013 | WO2013106012A1 Oral care formulations |
| 07/18/2013 | WO2013105895A1 A pharmaceutical composition comprising stable, amorphous hybrid nanopraticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component |
| 07/18/2013 | WO2013105894A1 A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component. |
| 07/18/2013 | WO2013105819A1 Stable pharmaceutical composition comprising eperisone or a pharmaceutically acceptable salt thereof and an acidifying agent |
| 07/18/2013 | WO2013105804A1 Cosmetic composition carrier containing urethane foam layer structure |
| 07/18/2013 | WO2013105101A1 Solid lipid nanoparticles entrapping hydrophilic/ amphiphilic drug and a process for preparing the same |
| 07/18/2013 | WO2013105092A1 Fixed dose combination therapy of parkinson's disease |
| 07/18/2013 | WO2013105026A1 A process for preparing solid lipid sustained release nanoparticles for delivery of vitamins |
| 07/18/2013 | WO2013104892A1 Application of high dose compounds via inhalation |
| 07/18/2013 | WO2013104876A1 Wound dressing |
| 07/18/2013 | WO2013104861A1 Injectable solution having a ph of 7 and including at least basal insulin, the pi of which is between 5.8 and 8.5, and a substituted co-poly(amino acid) |
| 07/18/2013 | WO2013104745A1 Pharmaceutical composition |
| 07/18/2013 | WO2013104698A1 Scarring reducing wound treatment |
| 07/18/2013 | WO2013104537A1 Packaging structure for biomedical films |
| 07/18/2013 | WO2013104399A1 Topical pharmaceutical compositions comprising bexarotene and a corticosteroids |
| 07/18/2013 | WO2013104346A1 Lipopolyamines of spermine type for construction of liposomal transfection systems |
| 07/18/2013 | WO2013104067A1 Reducible self-assembled micelle drug delivery systems |
| 07/18/2013 | WO2013071457A4 Injectable veterinary composition for controlled, sustained release of ceftiofur and florfenicol in animal species, based on polyhydroxybutyrate hydroxyvalerate (phbv) microparticles |
| 07/18/2013 | WO2013064900A8 Oral immediate release formulations for substituted quinazolinones |
| 07/18/2013 | WO2013056048A3 Nutritional products comprising beta-alanine |
| 07/18/2013 | WO2012175996A3 Drug delivery formulations |
| 07/18/2013 | WO2012140351A3 Caffeine and triacanthine composition for treating excess fat |
| 07/18/2013 | US20130184351 Lidocaine patch and methods of use thereof |
| 07/18/2013 | US20130184296 Parenteral solutions containing metolazone |
| 07/18/2013 | US20130184245 Endometriosis treatment |
| 07/18/2013 | US20130184243 Compositions of alkylating agents and methods of treating skin disorders therewith |
| 07/18/2013 | US20130184242 Pharmaceutical Composition for Topical Application |
| 07/18/2013 | US20130184216 Novel albumin-free factor viii formulations |
| 07/18/2013 | US20130183702 Protease selective supramolecular assemblies |
| 07/18/2013 | US20130183434 Mesalazine tablet having improved dissolution |
| 07/18/2013 | US20130183384 Immediate release multi unit pellet system |
| 07/18/2013 | US20130183382 Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same |
| 07/18/2013 | US20130183379 Graft copolymer polyelectrolyte complexes for drug delivery |
| 07/18/2013 | US20130183375 Method for formulating large diameter synthetic membrane vesicles |
| 07/18/2013 | US20130183374 Sustained release formulation of a non-steroidal anti-inflammatory drug |
| 07/18/2013 | US20130183373 Method for formulating large diameter synthetic membrane vesicles |
| 07/18/2013 | US20130183372 Method for formulating large diameter synthetic membrane vesicles |
| 07/18/2013 | US20130183371 Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent |
| 07/18/2013 | US20130183370 Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent |
| 07/18/2013 | US20130183365 Wound Healing Device and Method |
| 07/18/2013 | US20130183359 Polymeric compositions containing ir-emitting/absorbing additives and shaped articles comprised thereof |
| 07/18/2013 | US20130183358 Liposomes for the treatment of textile materials |
| 07/18/2013 | US20130183357 Oxidatively cross-linked protein-based encapsulates |
| 07/18/2013 | US20130183353 Low dosage forms of risedronate or its salts |
| 07/18/2013 | US20130183349 Method for controlled release of parathyroid hormone from cross-linked hyaluronic acid hydrogel |
| 07/18/2013 | US20130183251 Penetrating pharmaceutical foam |
| 07/18/2013 | US20130183250 Body cavity foams |
| 07/18/2013 | US20130183244 Rapid Diffusion of Large Polymeric Nanoparticles in the Mammalian Brain |
| 07/18/2013 | CA2860995A1 Pharmaceutical compositions and methods for their preparation |
| 07/18/2013 | CA2860973A1 A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component |
| 07/18/2013 | CA2860952A1 Fixed dose combination therapy of parkinson's disease |
| 07/18/2013 | CA2860932A1 A pharmaceutical composition comprising stable, amorphous hybrid nanopraticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component |
| 07/18/2013 | CA2857207A1 Topical pharmaceutical compositions comprising bexarotene and a corticosteroide |
| 07/18/2013 | CA2851827A1 Nanoparticles for controlling bleeding and drug delivery |
| 07/18/2013 | CA2832563A1 Multi-purpose lignin-carbohydrate binding system |
| 07/17/2013 | EP2615104A1 Hepatitis c virus liposome vaccine |
| 07/17/2013 | EP2614848A1 Inhaler and capsule for an inhaler |
| 07/17/2013 | EP2614846A1 Embolic agent and preparation method therefor |
| 07/17/2013 | EP2614844A1 Method for preparing drug inserts for sutained release of therapeutic agents |
| 07/17/2013 | EP2614833A1 Scarring reducing wound treatment |
| 07/17/2013 | EP2614820A1 Transdermal therapeutic system with a choline esterase inhibitor |